133427-08-4

Basic information

• Product Name: IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID
• Synonyms: IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID;H-imidazo[1,2-a]pyridine-8-carboxylic acid;Imidazo[1,2-a]pyridine-8-...;IMidazo[1,2-a]pyridin-8-carboxylic acid;H-iMidazo[1,2-a]pyridine-8-carbo×ylic acid
• CAS NO: 133427-08-4
• Molecular Formula: C₈H₆N₂O₂
• Molecular Weight: 162.15
• Product Categories: CHIRAL CHEMICALS
• Mol File: 133427-08-4.mol

Chemical Properties

• Appearance: /
• Density: 1.41
• Refractive Index: 1.676
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -0.61±0.41(Predicted)
• CAS DataBase Reference: IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID(133427-08-4)
• EPA Substance Registry System: IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID(133427-08-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-43
• Safety Statements: 36/37
• Hazardous Substances Data: 133427-08-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals for its potential anti-inflammatory, anti-cancer, and anti-viral properties, contributing to the development of new drugs with therapeutic benefits.
Used in Agrochemical Industry:
IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID is utilized as a building block in the creation of agrochemicals, where its unique chemical properties can be harnessed to develop new pesticides or other agricultural chemicals to improve crop protection and yield.
Used in Organic Materials Development:
IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID is used as a component in the development of organic materials, such as in the fabrication of organic electronic devices, due to its potential to enhance the performance and functionality of these materials.
Used in Materials Science:
IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID is employed in materials science research for its potential use in creating new materials with unique properties, leveraging its structural and reactive characteristics to innovate in this field.

InChI:InChI=1/C8H6N2O2/c11-8(12)6-2-1-4-10-5-3-9-7(6)10/h1-5H,(H,11,12)

Upstream product

• 107-20-0 2-chloroethanal 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 133427-07-3 methyl 8-imidazo<1,2-a>pyridinecarboxylate 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 

Downstream Products

• 1116691-26-9 3-bromoimidazo[1,2-a]pyridine-8-carboxylic acid 
• 885276-95-9 3-iodo-imidazo[1,2-a]pyridine-8-carboxylic acid methyl ester 
• 1300022-42-7 3-(4-fluorophenyl)-imidazo[1,2-a]pyridine-8-carboxylic acid 
• 133427-07-3 methyl 8-imidazo<1,2-a>pyridinecarboxylate 
• 1116690-51-7 (4-(2,4-difluorophenethyl)piperazin-1-yl)(imidazo[l,2-α]pyridin-8-yl)methanone 

Relevant articles and documents

Identification of fused bicyclic heterocycles as potent and selective 5-HT2A receptor antagonists for the treatment of insomnia

A series of fused bicyclic heterocycles was identified as potent and selective 5-HT2A receptor antagonists. Optimization of the series resulted in compounds that had improved PK properties, favorable CNS partitioning, good pharmacokinetic properties, and significant improvements on deep sleep (delta power) and sleep consolidation.

HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).

IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

rmidazo[l,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists

A series of pyrrolizidine esters, amides, and ureas was prepared and tested for 5-HT4 and 5-HT3 receptor binding, 5-HT4 receptor agonism in the rat tunica muscularis mucosae (TMM) assay, and for 5-HT3 receptor-mediated functional antagonism in the Bezold-Jarisch reflex assay. Several pyrrolizidine derivatives were identified with high affinity for the 5-HT4 receptor, including benzamide 12a (SC-53116), a potent and selective 5-HT4 partial agonist that exhibits efficacy in promoting antral contractions and activity in promoting gastric emptying in canine models. Also discovered were 5-HT4 receptor antagonists, including imidazopyridine amide 12h (SC-53606), which is a potent and selective 5-HT4 receptor antagonist with a pA2 value of 8.13 in the rat TMM assay. N-Methyl indole ester 13d was identified as a potent 5-HT 4 antagonist with a pA2 value of 8.93. High selectivity was observed for these pyrrolizidine derivatives versus other monoamine receptors, including 5-HT1, 5-HT2, D1, D 2, α1, α2, and β receptors. 2006 American Chemical Society.

Nicotinamide derivatives useful as PDE4 inhibitors

This invention relates to nicotinamide derivatives of general formula (I): in which R1, R2 and R3 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

Novel compounds

This invention relates to nicotinamide derivatives of general formula (I): in which R1, X, Y, Z and R2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.